The kit offers a significantly faster turn-around-time as it requires just 75 minutes to conduct the test without any cross-reactivity with other diseases.
The Dipcovan kit can detect both spike as well as nucleocapsid (S&N) proteins of SARS-CoV-2 virus with a high sensitivity of 97 % and specificity of 99%.
The kit has a shelf life of 18 months.
It has been developed in association with Vanguard Diagnostics Pvt Ltd.
Vanguard Diagnostics will commercially launch the product during the first week of June.
Readily available stock at the time of launch will be 100 kits (approximately 10,000 tests) with a production capacity of 500 kits/month after the launch.
The kit is expected to be available at about Rs 75 per test.
The Dipcovan kit was developed indigenously by the DRDO's scientists, followed by extensive validation on more than 1,000 patient samples at various Covid designated hospitals in Delhi.
Three batches of the product were validated during the last one year.
The antibody detection kit is approved by the Indian Council of Medical Research (ICMR) in April 2021.